deCODE biostructures Announces Fragments of Life™ Milestone and Extension with InterMune
News Jan 29, 2008
deCODE biostructures, Inc has announced that it successfully met a development milestone under its agreement with InterMune via delivery of multiple small molecule fragments to a proprietary protein target.
The structures represent chemotypes and provide new scaffolds for developing unique small molecule drugs. In connection with the achievement of this milestone, deCODE and InterMune agreed to extend their collaborative research agreement.
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019